|
Leukemia, Myelocytic, Acute
|
0.300 |
Biomarker
|
disease |
CTD_human |
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
|
26237430 |
2015 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
|
26237430 |
2015 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
|
26237430 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
The presence of anti-ENA and anti-dsDNA autoantibodies in SLE patients was associated with elevated levels of TLR7 and TLR9 respectively.
|
23564191 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
Systemic lupus erythematosus (SLE) patients have anti-nuclear autoantibodies directed against dsDNA and RNA-associated antigens (extractable nuclear antigens; ENA).
|
24659206 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
These results might suggest that Italian patients with SLE are, at least in part, different from lupus patients living in other geographical areas and suggest the association of DQw2 with the autoantibody response to ENA in SLE.
|
1954698 |
1991 |
|
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
ACA = anti-cardiolipin antibodies; ANF = anti-nuclear factor; anti-CCP = anti-cyclic citrullinated peptide; anti-dsDNA = anti-double-stranded DNA; anti-RNP = anti-ribonucleoprotein; anti-Scl70 = anti-topoisomerase I antibodies; anti-SM = anti-Smith antigen antibodies; anti-SS-A/Ro = anti-Sjögren syndrome-related antigen A (Ro); anti-SS-B/La = anti-Sjögren syndrome-related antigen B (La); anti-Tg = anti-thyroglobulin; anti-TPO = anti-thyroid peroxidase; ATD = autoimmune thyroid disease; ENA = extractable nuclear antigen; fT4 = free thyroxine; OR = odds ratio; RF = rheumatoid factor; SLE = systemic lupus erythematosus; SLEDAI = SLE Disease Activity Index; TD = thyroid dysfunction; TSH = thyroid-stimulating hormone; TT3 = total triiodothyronine.
|
28816533 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
Anti-dsDNA antibodies were higher in SLE and ENA showed the highest titers in MCTD.
|
30807792 |
2019 |
|
Stomach Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The Mena protein expression level was analyzed in paraffin-embedded GC samples and adjacent normal tissues by immunohistochemistry.
|
29113241 |
2017 |
|
Stomach Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PPARγ might inhibit the proliferation and migration of GC cell lines through suppressing the expression of TERT and ENAH.
|
26956036 |
2016 |
|
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity.
|
25556597 |
2015 |
|
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our research suggests that ENAH might play promoting functions in carcinogenesis and progression of gastric cancer, and may serve as a valuable prognostic marker for primary gastric adenocarcinoma patients.
|
29069803 |
2017 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression of ENAH isoform 11a has been shown to be elevated in breast cancers that express HER2.
|
26149387 |
2015 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Loss of CLK2 in luminal breast cancer cells leads to the upregulation of epithelial-to-mesenchymal transition (EMT)-related genes and a switch to mesenchymal splice variants of several genes, including ENAH (MENA).
|
25670169 |
2015 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MENA(INV) and FN levels were correlated in two breast cancer cohorts, and high levels of MENA(INV) were significantly associated with increased tumor recurrence as well as decreased patient survival.
|
26811325 |
2016 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our research suggests that ENAH might play promoting functions in carcinogenesis and progression of gastric cancer, and may serve as a valuable prognostic marker for primary gastric adenocarcinoma patients.
|
29069803 |
2017 |
|
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
PPARγ might inhibit the proliferation and migration of GC cell lines through suppressing the expression of TERT and ENAH.
|
26956036 |
2016 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity.
|
25556597 |
2015 |
|
Colorectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Association of genetic variants with colorectal cancer in the extended MENA region: A systematic review.
|
31612830 |
2020 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We also performed immunohistochemical analysis of the expression of hMena protein in 50 cases of paraffin-embedded archival colorectal tissues, and found that an elevated hMena expression is correlated to the cases with advanced TNM stages of colorectal carcinomas (P<0.001).
|
19082477 |
2009 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Loss of CLK2 in luminal breast cancer cells leads to the upregulation of epithelial-to-mesenchymal transition (EMT)-related genes and a switch to mesenchymal splice variants of several genes, including ENAH (MENA).
|
25670169 |
2015 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MENA(INV) and FN levels were correlated in two breast cancer cohorts, and high levels of MENA(INV) were significantly associated with increased tumor recurrence as well as decreased patient survival.
|
26811325 |
2016 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression of Mena protein in 81 specimens of HCC tissues was determined by immunohistochemistry.
|
24683008 |
2014 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
A high MENA protein level was associated with high mRNA levels of MENA, CD133, cytokeratin 19 (CK19), and epithelial cell adhesion molecule (EpCAM) in human HCC tissues.
|
28781954 |
2017 |
|
Ataxia Telangiectasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
ACA = anti-cardiolipin antibodies; ANF = anti-nuclear factor; anti-CCP = anti-cyclic citrullinated peptide; anti-dsDNA = anti-double-stranded DNA; anti-RNP = anti-ribonucleoprotein; anti-Scl70 = anti-topoisomerase I antibodies; anti-SM = anti-Smith antigen antibodies; anti-SS-A/Ro = anti-Sjögren syndrome-related antigen A (Ro); anti-SS-B/La = anti-Sjögren syndrome-related antigen B (La); anti-Tg = anti-thyroglobulin; anti-TPO = anti-thyroid peroxidase; ATD = autoimmune thyroid disease; ENA = extractable nuclear antigen; fT4 = free thyroxine; OR = odds ratio; RF = rheumatoid factor; SLE = systemic lupus erythematosus; SLEDAI = SLE Disease Activity Index; TD = thyroid dysfunction; TSH = thyroid-stimulating hormone; TT3 = total triiodothyronine.
|
28816533 |
2017 |